Bruker 9.4T/ 20cm BioSpec MR Scanner for Colorado Animal Imaging Shared Resources

用于科罗拉多州动物成像的布鲁克 9.4T/20cm BioSpec MR 扫描仪共享资源

基本信息

批准号：
9273825
负责人：
Natalie J. Serkova
金额：
$ 200万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-03-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9273825
关键词：
11 year old Aging Animals Area Award Biomedical Research Cancer Biology Clinical Sciences Colorado Contrast Media Development Doctor of Philosophy Elderly Equipment Functional Magnetic Resonance Imaging Funding Grant Image Imagery Imaging Techniques Institutes Magnetic Resonance Imaging Medical Metabolic Metabolism Minor Molecular Molecular Probes Neurosciences Phase Physiology Principal Investigator Protocols documentation RF coil Research Personnel Resolution Resource Sharing Small Animal Imaging Systems Technology The University of Colorado Cancer Center Time Translational Research United States National Institutes of Health Universities anatomic imaging animal imaging base cancer imaging cardiovascular visualization driving force high resolution imaging imaging scientist improved instrument instrumentation metabolic imaging microCT microPET microPET/CT microSPECT molecular imaging novel pre-clinical ranpirnase single photon emission computed tomography spectroscopic imaging

项目摘要

PROJECT SUMMARY AND ABSTRACT University of Colorado Animal Imaging Shared Resources (AISR) is applying for funds to purchase a Bruker 9.4 Tesla/ 20 cm BioSpec MRI scanner. The major users will be 18 investigators (with major NIH and DOD funds) from the University of Colorado Anschutz Medical Campus (AMC), with pending request for 5-10% of instrument time per investigator. Several minor users will be requesting an estimated 1-2% of instrument time per user. All users are supported by a total of 21 active and 6 pending R01 grants, several R21, DOD, K-, U- and P-type of awards. The requested scanner will become a part of the Colorado AISR which is substantially supported as a major Institutional Technology Core by the University of Colorado Cancer Center (UCCC, P30 CA046934-25) and the Colorado Clinical and Translational Sciences Institute (CCTSI, UL1TR001082). The AISR was initially funded in 2006, after a successful S10 shared grant instrumentation application (PI: N. Serkova, PhD) was awarded to purchase a Bruker 4.7 T/16 cm PharmaScan, which was the first small animal imaging system in Colorado. Since 2006, state-of-the-art animal scanners, advanced physiology-based imaging protocols and novel contrast agents/ molecular probes have revolutionized pre-clinical biomedical research at the Anschutz Medical Campus, allowing for non-invasive visualization of cancer biology, physiology and metabolism in a living animal. Based on the existing scientific demand and strong institutional commitment to the AISR, the present animal imaging equipment has expanded to include a Xenogen IVIS200, a Siemens Inveon microPET/CT, and a Mediso microSPECT/CT. Since it was established in 2006, the AISR has been utilized by 124 users (with over 45 of them being MRI-users), with an impressive number of federal grants awarded to support imaging-based translational science in Colorado. Three major areas of expertise have emerged: (i) oncologic imaging; (ii) neuroscience; and (iii) molecular imaging, with various established MR protocols utilizing the existing 4.7 Tesla scanner. The eleven-year old 4.7 Tesla PharmaScan provides reliable anatomical images with spatial resolution in the range of 150 microns. However, the major limitations of the PharmaScan, besides its advanced age and soon-to-be discontinued Bruker support, include the low field strength, limited RF coils and hardware capacities (low SNR, limited in-plane resolution) which are prohibitive for high-resolution imaging, spectroscopic imaging, advanced rapid imaging techniques and imaging of new contrast mechanisms. The sensitivity and image quality from the PharmaScan is not sufficient by today's standards. Therefore, the AISR is seeking to expand the existing aging MR technology with a new 9.4 Tesla BioSpec which will be highly desirable for our users in the areas of: (i) high-resolution anatomical imaging (<75 µm); (ii) EPI (fast BOLD and functional MRI); and (iii) metabolic 1H-MRS and spectroscopic imaging. In addition, fast cardiac imaging with phase-array coils are desirable. Some of these limitations can be overcome by use of microCT (improved spatial resolution), microPET/ SPECT(metabolic and molecular imaging), but the addition of high-field MRI is essential for a state-of-the-art AISR. The AISR team has assembled a strong group of NIH funded principal investigators in the areas of neuroscience, oncology and molecular imaging who are the driving force for assembling this application. The major and secondary users will be supported by a team of highly qualified translational imaging scientists, physicists, and chemists in order to form a successful platform for the development and application of high-resolution, functional, molecular and metabolic MR based protocols using the requested 9.4 Tesla Bruker BioSpec.

项目概要和摘要科罗拉多大学动物成像共享资源 (AISR) 正在申请资金购买布鲁克 9.4 Tesla/ 20 cm BioSpec MRI 扫描仪主要用户将是 18 名研究人员（主要有 NIH 和 DOD）。资金）来自科罗拉多大学安舒茨医学校区 (AMC)，待申请 5-10% 每个调查员的仪器时间。一些小用户将请求估计 1-2% 的仪器时间。所有用户均获得总共 21 个活跃的 R01 拨款和 6 个待定的 R01 拨款以及多个 R21、DOD、K-、U- 的支持。所请求的扫描仪将成为科罗拉多州 AISR 的一部分，这在很大程度上是必要的。作为主要机构技术核心得到科罗拉多大学癌症中心 (UCCC, P30 CA046934-25）和科罗拉多临床与转化科学研究所（CCTSI，UL1TR001082）。 AISR 最初于 2006 年在 S10 共享仪器拨款申请成功后获得资助（PI：N. Serkova 博士）被授予购买布鲁克 4.7 T/16 cm PharmaScan，这是第一台小动物科罗拉多州自 2006 年以来使用最先进的动物扫描仪，基于先进的生理学。成像协议和新型造影剂/分子探针彻底改变了临床前生物医学安舒茨医学园区的研究允许癌症生物学的非侵入性可视化，基于现有的科学需求和强大的机构。为了履行对 AISR 的承诺，现有的动物成像设备已扩展至包括 Xenogen IVIS200， AISR 成立于 2006 年，拥有一台西门子 Inveon microPET/CT 和一台 Mediso microSPECT/CT。已被 124 个用户使用（其中超过 45 个是 MRI 用户），其中联邦用户数量令人印象深刻拨款用于支持科罗拉多州基于成像的转化科学的三个主要专业领域。已经出现：（i）肿瘤成像；（ii）神经科学；和（iii）分子成像，并已建立了各种使用已有 11 年历史的 4.7 Tesla PharmaScan 提供 MR 协议。空间分辨率在 150 微米范围内的可靠解剖图像然而，主要的局限性。 PharmaScan 的缺点除了其年事已高和即将停止的布鲁克支持外，还包括低场强、有限的射频线圈和硬件能力（低信噪比、有限的面内分辨率）禁止高分辨率成像、光谱成像、先进的快速成像技术和成像 PharmaScan 的灵敏度和图像质量还不够。因此，AISR 正在寻求通过新的 9.4 来扩展现有的老化 MR 技术。 Tesla BioSpec 在以下领域非常适合我们的用户：(i) 高分辨率解剖学成像（<75 µm）；(ii) EPI（快速 BOLD 和功能 MRI）；以及 (iii) 代谢 1H-MRS 和光谱此外，使用相控阵线圈进行快速心脏成像也是可取的。通过使用 microCT（提高空间分辨率）、microPET/SPECT（代谢和分子成像），但高场 MRI 的添加对于最先进的 AISR 至关重要。组建了一个强大的团队，由 NIH 资助的神经科学、肿瘤学和分子成像是组装此应用程序的驱动力。将得到高素质转化成像科学家、物理学家和化学家团队的支持形成一个成功的平台，用于高分辨率、功能性、分子和基于代谢 MR 的协议使用要求的 9.4 Tesla Bruker BioSpec。